 |
Top 35 medical and healthcare startups in Switzerland
Oct 12, 2024 | By Jason Kwon | 17 |
1
Funding: $268M
Basilea Pharmaceutica is a commercial stage biopharmaceutical company that develops and commercializes innovative medicines in the therapeutic area of anti-infectives
Basilea Pharmaceutica is a commercial stage biopharmaceutical company that develops and commercializes innovative medicines in the therapeutic area of anti-infectives
2
Funding: $101.8M
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
3
Funding: $214.7M
SkyCell focuses on developing temperature controlled logistics containers for the pharmaceutical industry.
SkyCell focuses on developing temperature controlled logistics containers for the pharmaceutical industry.
4
Funding: $2.5B
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
5
Funding: $751.6M
ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers. ADC Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine (PBD) -based warheads to selectively kill cancer cells.
ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers. ADC Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine (PBD) -based warheads to selectively kill cancer cells.
6
Funding: $340.7M
MindMotionPro is a CE-Marked hospital based solution for early motor rehabilitation post-stroke. An engaging and motivational virtual reality rehabilitation program that supports individual recovery goal.
MindMotionPro is a CE-Marked hospital based solution for early motor rehabilitation post-stroke. An engaging and motivational virtual reality rehabilitation program that supports individual recovery goal.
7
Funding: $265.2M
Sophia Genetics aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning.
Sophia Genetics aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning.
8
Funding: $221.8M
Arvelle carries forward the European rights to cenobamate, an anti-epileptic drug for partial-onset seizures
Arvelle carries forward the European rights to cenobamate, an anti-epileptic drug for partial-onset seizures
9
Funding: $184M
ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.
ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.
10
Funding: $108.8M
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.
11
Funding: $100M
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases
12
Funding: $87.1M
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
13
Funding: $76M
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
14
Funding: $65.7M
NBE-Therapeutics develops next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.
NBE-Therapeutics develops next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.
15
Funding: $61M
Pioneering the next generation of non-viral gene therapy. Viral vectors have enabled early successes in the gene therapy space, but their immunogenicity, limited payload capacity and complex manufacturing are headwinds for the field. Anjarium is squarely focused on those challenges.
Pioneering the next generation of non-viral gene therapy. Viral vectors have enabled early successes in the gene therapy space, but their immunogenicity, limited payload capacity and complex manufacturing are headwinds for the field. Anjarium is squarely focused on those challenges.
17
Funding: $54.6M
GeNeuro develops innovative treatments against inflammatory and degenerative disorders associated with endogenous retroviruses.
GeNeuro develops innovative treatments against inflammatory and degenerative disorders associated with endogenous retroviruses.
18
Funding: $45.3M
Ava is a patented multi-sensor bracelet, which allows women to precisely and conveniently predict fertile days. Ava uses AI for big data analytics to track personal fertility cycles.
Ava is a patented multi-sensor bracelet, which allows women to precisely and conveniently predict fertile days. Ava uses AI for big data analytics to track personal fertility cycles.
19
Funding: $41.1M
Prexton Therapeutics has the mission to develop innovative drugs to improve the quality of life of people who suffer from Parkinson's disease and other brain disorders. Prexton Therapeutics has the expertise to design novel mGluR4 compounds as new treatment for Parkinson's disease.
Prexton Therapeutics has the mission to develop innovative drugs to improve the quality of life of people who suffer from Parkinson's disease and other brain disorders. Prexton Therapeutics has the expertise to design novel mGluR4 compounds as new treatment for Parkinson's disease.
20
Funding: $33.4M
Sensimed AG, a Swiss company, has developed a unique non-invasive soft contact lens-based solution, the SENSIMED Triggerfish, with the aim of revolutionizing glaucoma management by providing an automated recording of continuous ocular dimensional change over 24 hours.
Sensimed AG, a Swiss company, has developed a unique non-invasive soft contact lens-based solution, the SENSIMED Triggerfish, with the aim of revolutionizing glaucoma management by providing an automated recording of continuous ocular dimensional change over 24 hours.
